



BIOHEART

Media Contact: Carissa Matton
Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 954.835.1500
cmatton@bioheartinc.com

For Immediate Release

US Stem Cell Clinic Increases Staff to Support Patient Demand; Marketing

Sunrise, FL – April 15, 2015 – Bioheart, Inc., a Florida Corporation

(BHRT.OB)announces today that its US Stem Cell Clinic division has increased its staff to support increasing patient demand and the creation and launch of new marketing initiatives.

“The demand for regenerative medicine / cellular therapeutics in the US is increasing,” said Kristin Comella, Chief Scientific Officer. “Physicians and patients are increasingly recognizing the extraordinary benefits of regenerative medicine / cellular therapeutics. Using the cells from our own bodies to treat and potentially cure ourselves of ailments is smart medicine. The human body is the most complex machine ever created. Imbedded in our own humanity are the cells (stem cells) capable of keeping us functioning as we were designed. Physicians across the US are using regenerative medicine / cellular therapeutics to treat autoimmune, neurologic, orthopedic, dermatologic and dental conditions. US Stem Cell Clinic is expanding its staff to enhance its coordination of clinic scheduling and patient management. We value highly our patients and we want their experience with us to be the best it can be. Further, expanding our marketing outreach is good business. To date, we have relied on organic, word of mouth marketing to advance our patient numbers. This has worked very well for us, but we are convinced that extending our message through various media outlets will be beneficial for us and the patients who do not yet know the benefits of regenerative medicine.”

“We have calculated the return on investment for increasing our US Stem Cell Clinic staff and we are confident that the personnel investments we are making today will yield substantial returns in the coming months,” said Mike Tomas, President and Chief Executive Officer. “Our commitment to our US Stem Cell Training and US Stem Cell Clinic divisions is a key driver in our business expansion strategy. Sales and profits are good for us and for our shareholders and this is where attention lies.”

About Bioheart, Inc.

Bioheart, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell

storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

US Stem Cell Training, (“SCT”), an operating division of Bioheart, Inc., is a content developer of regenerative medicine / cell therapy informational and training materials for physicians and patients. SCT also provides in-person and online training courses which are delivered through in-person presentations at SCT’s state of the art facilities and globally at university, hospital and physician’s office locations as well as through online webinars. Additionally, SCT provides hands-on clinical application training for physicians and health care professionals interested in providing regenerative medicine / cell therapy procedures.

Vetbiologics, (“VBI”), an operating division of Bioheart, Inc., is a veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the highest quality regenerative medicine therapies to dogs, cats and horses. VBI provides veterinarians with extensive regenerative medicine capabilities including the ability to isolate regenerative stem cells from a patient’s own adipose (fat) tissue directly on-site within their own clinic or stall-side. VBI regenerative medicine technologies are designed, implemented and produced according to the highest standards. VBI follows the FDA guidelines for human cellular therapy production which means each product produced must be validated and must pass stringent criteria.

US Stem Cell Clinic, LLC, (“SCC”), a partially owned investment of Bioheart, Inc., is a physician run regenerative medicine / cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases. SCC is operating in compliance with the FDA 1271s which allow for same day medical procedures to be considered the practice of medicine. We isolate stem cells from bone marrow and adipose tissue and also utilize platelet rich plasma.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Reports on Form 10-Q.